Heinz-Josef Lenz, MD, and Marc Ychou, MD, on Treating mCRC With Initially Nonresectable Liver Metastases
2016 ASCO Annual MeetingHeinz-Josef Lenz, MD, of the University of Southern California, and Marc Ychou, MD, of the Centre Régional de Lutte Contre Le Cancer, discuss study findings on FOLFIRINOX combined with targeted therapy according to RAS status for colorectal cancer patients with initially nonresectable liver metastases (Abstract 3512).
Related Videos
Toni K. Choueiri, MD, and Paul L. Nguyen, MD, on Prostate Cancer: Expert Perspectives on Four Studies
Toni K. Choueiri, MD, and Paul L. Nguyen, MD, both of the Dana-Farber Cancer Institute, discuss four key studies on high- and intermediate-risk prostate cancer, as...
David F. McDermott, MD, and Toni K. Choueiri, MD, on Advanced RCC: Nivolumab in Previously Treated Patients
David F. McDermott, MD, of Beth Israel Deaconess Medical Center, and Toni K. Choueiri, MD, of the Dana-Farber Cancer Institute, discuss an update on data from phase I...
Patricia J. Goldsmith on Patient Access and Engagement: Results of the CancerCare Report
Patricia J. Goldsmith, Chief Executive Officer of CancerCare, which provides free, professional support services to anyone affected by cancer, discusses findings from six dis...
Jonathan E. Rosenberg, MD, and Toni K. Choueiri, MD, on Bladder Cancer: Mutation Burden and Atezolizumab
Jonathan E. Rosenberg, MD, of Memorial Sloan Kettering Cancer Center, and Toni K. Choueiri, MD, of the Dana-Farber Cancer Institute, discuss mutation burden—its role ...
Nagi S. El-Saghir, MD, PhD, and Mary Gospodarowicz, MD, on The Middle Eastern Perspective of Cancer Research
Nagi S. El-Saghir, MD, of the American University of Beirut, and Mary Gospodarowicz, MD, of the Princess Margaret Hospital, discuss oncology from an international poi...
